Status:

COMPLETED

Prevention of Postpartum Hemorrhage With Tranexamic Acid

Lead Sponsor:

George Washington University

Collaborating Sponsors:

National Institutes of Health (NIH)

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Postpartum Hemorrhage

Eligibility:

FEMALE

18-49 years

Phase:

PHASE2

Brief Summary

Postpartum hemorrhage is a significant contributor to maternal morbidity and mortality and is worldwide. TXA has recently been proven to reduce mortality when given to women in setting of diagnosed PP...

Detailed Description

Conduct a prospective, open-label, dose finding PK study in 30 pregnant 3rd trimester women scheduled for non-emergent cesarean section who are at risk for hemorrhage. Three doses of the drug will be ...

Eligibility Criteria

Inclusion

  • Women who are undergoing medically indicated cesarean section at greater than 34+0 weeks gestation or women undergoing elective cesarean section at 39+0 weeks gestation in accordance with recommendations from the American Congress of Obstetricians and Gynecologists
  • Pregnant women with normal serum creatinine (serum creatinine \< 0.9)
  • Women between the ages of 18 and 50 years old

Exclusion

  • Patients younger than 18 or older than 50
  • women with active thrombotic or thromboembolic disease
  • Women with a history of arterial or venous thromboembolic event
  • Women with inherited thrombophilia or preexisting conditions that predisposes them to thromboembolic events (i.e. lupus, antiphospholipid syndrome)
  • Women with a subarachnoid hemorrhage
  • Women with acquired defective color vision
  • history of seizure disorder
  • known renal dysfunction
  • multiple gestations (Twin or triplet pregnancies)
  • Hypersensitivity to Tranexamic acid or anti-fibrinolytic therapy
  • History of liver dysfunction

Key Trial Info

Start Date :

January 2 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2023

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT03287336

Start Date

January 2 2018

End Date

September 30 2023

Last Update

March 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

James Slota

Washington D.C., District of Columbia, United States, 20037